Aslan Pharmaceuticals Singapore Subsidiary Files for Voluntary Liquidation

Dow Jones07-17

By Denny Jacob

Aslan Pharmaceuticals' operating subsidiary in Singapore filed for voluntary liquidation.

The clinical stage, immunology-focused biopharmaceutical company said Wednesday that the decision follows a review by the board of its subsidiary Aslan Pharmaceuticals Pte's financial position and strategic alternatives. All employees of Aslan Pharmaceuticals Pte and Aslan Pharmaceuticals $(USA)$ have been terminated.

Luke Anthony Furler and Tan Kim Han were appointed joint and several provisional liquidators. They will be responsible for the orderly winding up of Aslan Pharmaceuticals Pte's affairs including seeking potential strategic alternatives for its development programs and the company's primary assets.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

July 17, 2024 07:54 ET (11:54 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2452158013?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-17 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452158013","market":"sg","top_or_hot":-1,"title":"Aslan Pharmaceuticals Singapore Subsidiary Files for Voluntary Liquidation","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Aslan Pharmaceuticals' operating subsidiary in Singapore filed for voluntary liquidation. \n</p>\n<p>\n  The clinical stage, immunology-focused biopharmaceutical company said Wednesday that the decision follows a review by the board of its subsidiary Aslan Pharmaceuticals Pte's financial position and strategic alternatives. All employees of Aslan Pharmaceuticals Pte and Aslan Pharmaceuticals <a href=\"https://laohu8.com/S/USA\">$(USA)$</a> have been terminated. \n</p>\n<p>\n  Luke Anthony Furler and Tan Kim Han were appointed joint and several provisional liquidators. They will be responsible for the orderly winding up of Aslan Pharmaceuticals Pte's affairs including seeking potential strategic alternatives for its development programs and the company's primary assets. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2024 07:54 ET (11:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aslan Pharmaceuticals Singapore Subsidiary Files for Voluntary Liquidation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAslan Pharmaceuticals Singapore Subsidiary Files for Voluntary Liquidation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-17 19:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Denny Jacob \n\n\n \n\n\n  Aslan Pharmaceuticals' operating subsidiary in Singapore filed for voluntary liquidation. \n\n\n  The clinical stage, immunology-focused biopharmaceutical company said Wednesday ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2452158013","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452158013","pubTimestamp":1721217240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aslan Pharmaceuticals' operating subsidiary in Singapore filed for voluntary liquidation.The clinical stage, immunology-focused biopharmaceutical company said Wednesday that the decision follows a review by the board of its subsidiary Aslan Pharmaceuticals Pte's financial position and strategic alternatives. All employees of Aslan Pharmaceuticals Pte and Aslan Pharmaceuticals  have been terminated.Luke Anthony Furler and Tan Kim Han were appointed joint and several provisional liquidators. They will be responsible for the orderly winding up of Aslan Pharmaceuticals Pte's affairs including seeking potential strategic alternatives for its development programs and the company's primary assets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","USA":"Liberty All-Star Equity Fund","BK4139":"生物科技","ASLN":"ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)"},"translate_title":"阿斯兰制药新加坡子公司申请自愿清算","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"USA":1,"ASLN":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  Aslan Pharmaceuticals' operating subsidiary in Singapore filed for voluntary liquidation. \n\n\n  The clinical stage, immunology-focused biopharmaceutical company said Wednesday that the decision follows a review by the board of its subsidiary Aslan Pharmaceuticals Pte's financial position and strategic alternatives. All employees of Aslan Pharmaceuticals Pte and Aslan Pharmaceuticals $(USA)$ have been terminated. \n\n\n  Luke Anthony Furler and Tan Kim Han were appointed joint and several provisional liquidators. They will be responsible for the orderly winding up of Aslan Pharmaceuticals Pte's affairs including seeking potential strategic alternatives for its development programs and the company's primary assets. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2024 07:54 ET (11:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452158013"}